Loading...

News List

1.55亿美元!恒瑞医药又一款创新药出海

2023-10-09


1.55亿美元!恒瑞医药又一款创新药出海

恒瑞医药宣布与印度瑞迪博士实验室(“Dr. Reddy's”)达成协议,将具有自主知识产权的靶向药物马来酸吡咯替尼片目印度地区开发和商业化权利有偿许可给Dr. Reddy's。Dr. Reddy's 将向恒瑞支付300万美元的首付款,不超过1.525亿美元的销售里程碑款。将向恒瑞支付达到实际年净销售额两位数比例的销售提成。

Pre: Bagel Biologics receives approval to initiate Phase I clinical trial of TCR cell therapy

Next: 155 million dollars! Hengrui Medicine has another innovative drug to go to sea

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.